Evidence map›Paper›PMID 31440468›Full record

ArticleFrontiers in oncology2019

UNC13C Suppress Tumor Progression via Inhibiting EMT Pathway and Improves Survival in Oral Squamous Cell Carcinoma.

Bharath Kumar Velmurugan, Kun-Tu Yeh, Ming-Ju Hsieh, Chung-Min Yeh, Chia-Chieh Lin, Chuan-Yu Kao, Lan-Ru Huang, Shu-Hui Lin

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Comprehensive Genetic Study of Malignant Cervical Paraganglioma.International journal of molecular sciences · 2023
    Article
  7. Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  8. Article
  9. Article
  10. Review
  11. Differences Between Sorafenib and Lenvatinib Treatment from Genetic and Clinical Perspectives for Patients with Hepatocellular Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Bharath Kumar VelmuruganToxicology and Biomedicine Research Group, Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City, Vietnam.
Kun-Tu YehDepartment of Pathology, Changhua Christian Hospital, Changhua City, Taiwan.
Ming-Ju HsiehInstitute of Medicine, Chung Shan Medical University, Taichung City, Taiwan.
Chung-Min YehDepartment of Pathology, Changhua Christian Hospital, Changhua City, Taiwan.
Chia-Chieh LinOral Cancer Research Center, Changhua Christian Hospital, Changhua City, Taiwan.
Chuan-Yu KaoDepartment of Pathology, Changhua Christian Hospital, Changhua City, Taiwan.
Lan-Ru HuangDepartment of Medical Laboratory Science and Biotechnology, Central Taiwan University of Science and Technology, Taichung City, Taiwan.
Shu-Hui LinDepartment of Pathology, Changhua Christian Hospital, Changhua City, Taiwan.
Changhua Christian Hospital · TWCentral Taiwan University of Science and Technology · TWChung Shan Medical University · TWKang-Ning Junior College of Medical Care and Management · TWTon Duc Thang University · VN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Potential function of UNC13C in variety of cancers including, oral squamous cell carcinoma (OSCC) remains obscure. In the present study, immunohistochemical staining in tissue microarrays containing 268 OSCC samples showed that UNC13C protein levels were inversely correlated with AJCC Stage III and IV (

Indexed as

Claudin1EMToral canceroverall survival rateUNC13CVimentin

Identifiers

PMID31440468
PMCPMC6694713
OpenAlexW2962693485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.